Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Sotagliflozin (Inpefa) is indicated to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus with chronic kidney disease and other cardiovascular risk factors.
• The information is derived from a review of 17 systematic reviews/meta-analyses studies.
• Comparative analysis shows sotagliflozin significantly improves cardiovascular mortality, hospitalizations, and urgent heart failure visits compared to dapagliflozin.
• Benefits are consistent across patients with HFpEF (Heart Failure with Preserved Ejection Fraction) regardless of diabetes status.
• In populations with type 2 diabetes and chronic kidney disease at high cardiovascular risk, sotagliflozin effectively reduces major adverse cardiovascular events (MACE), heart failure hospitalization (HHF), and cardiovascular death.
• Increased risks were noted for genital mycotic infections, specific acidosis-related events, and diarrhea in both type 1 and type 2 diabetes patients on sotagliflozin.
• Compared to other SGLT2 inhibitors like empagliflozin or dapagliflozin, sotagliflozin shows superior benefits in reducing heart failure hospitalizations but similar benefits regarding all-cause mortality and overall cardiovascular outcomes.
• Dual inhibition mechanism via SGLT1/2 by sotagliflozin may offer additional glycemic control advantages potentially leading to better overall cardiovascular outcomes.